TY - JOUR
T1 - HLA and prognostic factors in primary breast cancer
AU - Iaffaioli, R. V.
AU - Maio, M.
AU - Ruggiero, G.
AU - De Felice, M.
AU - Ungaro, A.
AU - Del Vecchio, L.
AU - Rosato, G. B.
AU - Bianco, A. R.
AU - Zappacosta, S.
PY - 1985
Y1 - 1985
N2 - A group of 157 women with primary breast cancer (BC) were typed for HLA antigens, and gene frequencies to those of 327 control healthy individuals. Diagnosis of BC was made for all patients on surgical mastectomy specimens; histologic grading, estrogen (ER) and progesterone (PgR) receptors were determined on all primary tumors. Typed antigens included the majority of the specificities controlled by the HLA-A, -B and -C loci, according to the 8th International Histocompatibility Testing Workshop recommendations. No significant discrepancy in their frequencies was found in the undivided sample as compared to controls. The analysis of HLA gene frequency was extended to subsets of patients identified by the following prognostic features: (a) age at tumor diagnosis (pre-menopause vs. post-menopause); (b) receptor status (presence vs. absence of ER and PgR); (c) mammary gland dysplasia (presence vs. absence); (d) histologic grade (grade 3 vs. grades 1 and 2 combined); (e) time to relapse before or after 24 months following mastectomy). A moderate deviation from normal of some genes was found in several subsets, often affecting only one of the antithetical subgroups (feature present vs. feature absent). In the instance of B5, the increase in frequency of the gene in one of the subset pair (ER + subjects) was balanced by a decreased of the same gene in the counterpart (ER-subjects). Increased frequencies were found for the B7 gene in the following prognostic groups: (a) lack of ER (0.08); (b) lack of PgR (0.09; (c) absence of mammary dysplasia (0.075); (d) histologic grade 3 (0.10); and (e) premenopause (0.12), the last two showing significant divergence from normal. When features (d) and (e) on the one hand and (a),(b),(d) and (e) on the other were combined, B7 reached frequencies of 0.18 (p <5 x 10-4) and of 0.29 (p <5 x 10-6), respectively.
AB - A group of 157 women with primary breast cancer (BC) were typed for HLA antigens, and gene frequencies to those of 327 control healthy individuals. Diagnosis of BC was made for all patients on surgical mastectomy specimens; histologic grading, estrogen (ER) and progesterone (PgR) receptors were determined on all primary tumors. Typed antigens included the majority of the specificities controlled by the HLA-A, -B and -C loci, according to the 8th International Histocompatibility Testing Workshop recommendations. No significant discrepancy in their frequencies was found in the undivided sample as compared to controls. The analysis of HLA gene frequency was extended to subsets of patients identified by the following prognostic features: (a) age at tumor diagnosis (pre-menopause vs. post-menopause); (b) receptor status (presence vs. absence of ER and PgR); (c) mammary gland dysplasia (presence vs. absence); (d) histologic grade (grade 3 vs. grades 1 and 2 combined); (e) time to relapse before or after 24 months following mastectomy). A moderate deviation from normal of some genes was found in several subsets, often affecting only one of the antithetical subgroups (feature present vs. feature absent). In the instance of B5, the increase in frequency of the gene in one of the subset pair (ER + subjects) was balanced by a decreased of the same gene in the counterpart (ER-subjects). Increased frequencies were found for the B7 gene in the following prognostic groups: (a) lack of ER (0.08); (b) lack of PgR (0.09; (c) absence of mammary dysplasia (0.075); (d) histologic grade 3 (0.10); and (e) premenopause (0.12), the last two showing significant divergence from normal. When features (d) and (e) on the one hand and (a),(b),(d) and (e) on the other were combined, B7 reached frequencies of 0.18 (p <5 x 10-4) and of 0.29 (p <5 x 10-6), respectively.
UR - http://www.scopus.com/inward/record.url?scp=0021847301&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021847301&partnerID=8YFLogxK
U2 - 10.1002/ijc.2910350503
DO - 10.1002/ijc.2910350503
M3 - Article
C2 - 3873417
AN - SCOPUS:0021847301
SN - 0020-7136
VL - 35
SP - 581
EP - 585
JO - International Journal of Cancer
JF - International Journal of Cancer
IS - 5
ER -